Search by Author
Search by Journal
Search by Tag
Search by Date
Modelling Micro-Elimination: Third-Trimester Tenofovir Prophylaxis for Perinatal Transmission of Hepatitis B in the Remote Dolpa District of Nepal
Hepatitis B (HBV) prevalence is very high in pregnant women in the Dolpa district of Nepal, a region characterised by a remote geographic landscape and low vaccination coverage. Using mathematical modelling, we evaluated the impact…
Opportunistic co-screening for HCV and COVID-19-related services: A creative response with a need for thoughtful reflection
Summary At a time when hepatitis C virus clearance can be obtained by DAAs in almost all infected patients, global infection burden control is an objective within reach, even if achieving the WHO HCV elimination…
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
Summary Background Since the release of the first global hepatitis elimination targets in 2016, and until the COVID-19 pandemic started in early 2020, many countries and territories were making progress toward hepatitis C virus (HCV) elimination. This…
Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting
Le LV, Blach S, Rewari B, Chan P, Fuqiang C, Ishikawa N, Sharma M, Mangadan-Konath N, Razavi H, Low-Beer D, Razavi-Shearer D. Progress towards achieving viral hepatitis B and C elimination in the Asia and…
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, Ekstedt M, Esmat G, George J, Marchesini G, Novak K, Ocama P, Ratziu V, Razavi H, Romero-Gómez M, Silva M, Spearman CW, Tacke…
HCV disease burden and population segments in Switzerland
Summary Background Switzerland has made strides towards hepatitis C virus elimination, but as of 2019, elimination was not guaranteed. However, political interest in viral hepatitis has been increasing. We sought to develop a better understanding…
Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies
Trivedi PJ, Bowlus CL, Yimam KK, Razavi H, Estes C. Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. Clin Gastroenterol Hepatol. 2021 Aug 30:S1542-3565(21)00919-8. doi: 10.1016/j.cgh.2021.08.039. Epub ahead…
Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world
Toor J, Echeverria-Londono S, Li X, Abbas K, Carter ED, Clapham HE, Clark A, de Villiers MJ, Eilertson K, Ferrari M, Gamkrelidze I, Hallett TB, Hinsley WR, Hogan D, Huber JH, Jackson ML, Jean K,…
Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19
Blach S, Blomé M, Duberg AS, Jerkeman A, Kåberg M, Klasa PE, Lagging M, Razavi-Shearer D, Razavi H, Aleman S. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of…
COVID-19 and global HCV elimination efforts
COVID-19 and global HCV elimination efforts. Sarah Blach, MHS, CPH. HCV Team Lead, CDA Foundation, Lafayette, CO, USA. EASL: International Liver Foundation. April 2020.
Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study
Li X, Mukandavire C, Cucunubá ZM, Echeverria Londono S, Abbas K, Clapham HE, Jit M, Johnson HL, Papadopoulos T, Vynnycky E, Brisson M, Carter ED, Clark A, de Villiers MJ, Eilertson K, Ferrari MJ, Gamkrelidze…
Vaccine Impact Modelling Consortium. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study
Li X, Mukandavire C, Cucunubá ZM, Echeverria Londono S, Abbas K, Clapham HE, Jit M, Johnson HL, Papadopoulos T, Vynnycky E, Brisson M, Carter ED, Clark A, de Villiers MJ, Eilertson K, Ferrari MJ, Gamkrelidze…
Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study
Ellen Dugan, Sarah Blach, Mia Biondi, Zongzhen Cai, Mindi DePaola, Chris Estes, Jordan Feld, Ivane Gamkrelidze, Shyamasundaran Kottilil, Siya Ma, Poonam Mathur, Shauna Montoya, Devin Razavi-Shearer, Kathryn Razavi-Shearer, Sarah Robbins-Scott, Jonathan Schmelzer, Homie Razavi,Global prevalence…
Progress towards hepatitis C virus elimination in high-income countries: An updated analysis
Gamkrelidze I, Pawlotsky JM, Lazarus JV, Feld JJ, Zeuzem S, Bao Y, Gabriela Pires Dos Santos A, Sanchez Gonzalez Y, Razavi H. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. Liver…
The cost-effectiveness of hepatitis C virus elimination in low- and middle-income countries
Razavi H. The cost-effectiveness of hepatitis C virus elimination in low- and middle-income countries. J Viral Hepat. 2021 Feb;28(2):445. doi: 10.1111/jvh.13442. Epub 2020 Dec 1. PMID: 33205589.
Strategies to eliminate hepatitis C in Croatia, a modelling study
Vince, A., Dugan, E., Nemeth-Blažić, T., Filipec, T., Hrstic, I., Lukšić, B., Nonkovic, D., Reic, T., Coleman, S., Razavi, H., Blach, S. (2020). Strategies to eliminate hepatitis C in Croatia, a modelling study. Liječnički vjesnik, 142 (9-10),…
A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia
Sanai FM, Alghamdi M, Dugan E, Alalwan A, Al-Hamoudi W, Abaalkhail F, AlMasri N, Razavi-Shearer D, Razavi H, Schmelzer J, Alfaleh FZ. A tool to measure the economic impact of Hepatitis B elimination: A case…
The case for simplifying and using absolute targets for viral hepatitis elimination goals
Polaris Observatory Collaborators. The case for simplifying and using absolute targets for viral hepatitis elimination goals. J Viral Hepat 2021;28:12–19. Summary The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis,…
Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model — Tashkent, Uzbekistan, December 6, 2019–March 15, 2020
Dunn R, Musabaev E, Razavi H, Sadirova S, Bakieva S, Razavi-Shearer K, Brigida K, Kamili S, Averhoff F, Nasrullah M. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model – Tashkent,…
Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models
de Villiers MJ, Gamkrelidze I, Hallett TB, Nayagam S, Razavi H, Razavi-Shearer D. Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models. PLoS One. 2020 Aug…
Impact of COVID-19 on global HCV elimination efforts
Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, Gamkrelidze I, Ma S, Pawlotsky JM, Razavi-Shearer D, Razavi H, Waked I, Zeuzem S, Craxi A. Impact of COVID-19 on global HCV elimination…
The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data
Palayew A, Stumo SR, Cooke GS, Hutchinson SJ, Jauffret-Roustide M, Maticic M, Harris M, Metwally AM, Razavi H, Lazarus JV; Hep-CORE Study Group. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking…
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?
Palayew A, Razavi H, Hutchinson SJ, Cooke GS, Lazarus JV. Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C? Lancet Gastroenterol Hepatol. 2020 Oct;5(10):948-953. doi: 10.1016/S2468-1253(20)30011-X. Epub…
Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
Kondili LA, Blach S, Razavi H, Craxì A. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination? Ann Ist Super Sanita. 2020…
Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Authors’ reply
Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, Hu TH, Huang JF, Jang BK, Jun DW, Kao JH, Lee JW, Lin HC, Razavi-Shearer K, Seto WK, Wong GL, Wong VW, Razavi…
Global Epidemiology of Viral Hepatitis
Razavi H. Global Epidemiology of Viral Hepatitis. Gastroenterol Clin North Am. 2020 Jun;49(2):179-189. doi: 10.1016/j.gtc.2020.01.001. PMID: 32389357. Summary Viral hepatitis (hepatitis A, B, C, D, and E) is the leading cause of inflammation of liver…
Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study
Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, Marotta P, Elkhashab M, Bajaj HS, Estes C, Razavi H. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study. CMAJ…
Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model
Binka M, Janjua NZ, Grebely J, Estes C, Schanzer D, Kwon JA, Shoukry NH, Kwong JC, Razavi H, Feld JJ, Krajden M. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a…
A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea
Won YK, Kang KS, Gonzalez YS, Razavi H, Dugan E, Han KH, Ahn SH, Jeon MY, Kim DY. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in…
Optimization of hepatitis C virus screening strategies by birth cohort in Italy
Kondili LA, Gamkrelidze I, Blach S, Marcellusi A, Galli M, Petta S, Puoti M, Vella S, Razavi H, Craxi A, Mennini FS; PITER collaborating group. Optimization of hepatitis C virus screening strategies by birth cohort…
A micro-elimination approach to addressing hepatitis C in Turkey
Idilman, R., Razavi, H., Robbins-Scott, S. et al. A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Serv Res 20, 249 (2020). https://doi.org/10.1186/s12913-020-5019-8 Summary Background In 2016, WHO passed the Global Health Sector Strategy on Viral Hepatitis (GHSS),…
Modelling NAFLD disease burden in four Asian regions-2019-2030
Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, Hu TH, Huang JF, Jang BK, Jun DW, Kao JH, Lee JW, Lin HC, Razavi-Shearer K, Seto WK, Wong GL, Wong VW, Razavi…
Nonalcoholic fatty liver disease burden: Australia, 2019-2030
Adams LA, Roberts SK, Strasser SI, Mahady SE, Powell E, Estes C, Razavi H, George J. Nonalcoholic fatty liver disease burden: Australia, 2019-2030. J Gastroenterol Hepatol. 2020 Sep;35(9):1628-1635. doi: 10.1111/jgh.15009. Epub 2020 Feb 26. PMID:…
Global prevalence of hepatitis C virus in children in 2018: a modelling study
Schmelzer J, Dugan E, Blach S, Coleman S, Cai Z, DePaola M, Estes C, Gamkrelidze I, Jerabek K, Ma S, Montoya S, Razavi-Shearer D, Razavi-Shearer K, Robbins-Scott S, Razavi H, El Sayed MH. Global prevalence…
Nonalcoholic fatty liver disease burden – Switzerland 2018-2030
Goossens N, Bellentani S, Cerny A, Dufour JF, Jornayvaz FR, Mertens J, Moriggia A, Muellhaupt B, Negro F, Razavi H, Semela D, Estes C. Nonalcoholic fatty liver disease burden – Switzerland 2018-2030. Swiss Med Wkly….
Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach
Benzaken AS, Girade R, Catapan E, Pereira GFM, Almeida EC, Vivaldini S, Fernandes N, Razavi H, Schmelzer J, Ferraz ML, Ferreira PRA, Pessoa MG, Martinelli A, Souto FJD, Walsh N, Mendes-Correa MC. Hepatitis C disease…
Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake – a modeling study
Kwon JA, Dore GJ, Grebely J, Hajarizadeh B, Guy R, Cunningham EB, Power C, Estes C, Razavi H, Gray RT; HCV Estimates and Projections Reference Group. Australia on track to achieve WHO HCV elimination targets…
The hepatitis B epidemic and the urgent need for cure preparedness
Lazarus JV, Block T, Bréchot C, Kramvis A, Miller V, Ninburg M, Pénicaud C, Protzer U, Razavi H, Thomas LA, Wallace J, Cowie BC. The hepatitis B epidemic and the urgent need for cure preparedness….
Global, regional, and country-level estimates of hepatitis C virus infection among people who have recently injected drugs
Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, Vickerman P, Blach S, Cunningham EB, Dumchev K, Lynskey M, Stone J, Trickey A, Razavi H, Mattick RP, Farrell M, Dore GJ, Degenhardt…
HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era
Gountas I, Sypsa V, Blach S, Razavi H, Hatzakis A. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. PLoS One. 2018 Aug 16;13(8):e0202109. doi: 10.1371/journal.pone.0202109. PMID: 30114207; PMCID: PMC6095544. Summary…
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco…
Modeling the epidemiological landscape of chronic hepatitis C in a sub-Saharan African country – what is needed to achieve elimination by 2030 in Burundi
Ntagirabiri, R. , Robbins, S. , Barasukana, P. , Munezero, B. and Manirakiza, M. (2018) Modeling the Epidemiological Landscape of Chronic Hepatitis C in a Sub-Saharan African Country: What Is Needed to Achieve Elimination by…
Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
Schaefer B, Viveiros A, Al-Zoairy R, Blach S, Brandon S, Razavi H, Dorn L, Finkenstedt A, Effenberger M, Graziadei I, Sarcletti M, Tilg H, Zoller H. Disease burden of hepatitis C in the Austrian state…
The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations
Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, Hatzakis A, Jadoul M, Prestileo T, Razavi H, Rockstroh JK, Wiktor SZ, Colombo M. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and…
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini…
Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030
Alswat K, Aljumah AA, Sanai FM, Abaalkhail F, Alghamdi M, Al Hamoudi WK, Al Khathlan A, Al Quraishi H, Al Rifai A, Al Zaabi M, Babatin MA, Estes C, Hashim A, Razavi H. Nonalcoholic fatty…
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403. doi: 10.1016/S2468-1253(18)30056-6. Epub 2018 Mar 27. PMID: 29599078. Summary Collaborators Polaris Observatory…
Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe
Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün…
The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up
Hecht R, Hiebert L, Spearman WC, Sonderup MW, Guthrie T, Hallett TB, Nayagam S, Razavi H, Soe-Lin S, Vilakazi-Nhlapo K, Pillay Y, Resch S. The investment case for hepatitis B and C in South Africa:…
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1….
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030
Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, Müllhaupt B, Rauch A, Razavi H, Schmid P, Semela D, Stoeckle M, Negro F. Hepatitis C virus dynamics among intravenous drug users suggest…
Strategies to manage hepatitis C virus infection disease burden—Volume 4
Chen DS, Hamoudi W, Mustapha B, Layden J, Nersesov A, Reic T, Garcia V, Rios C, Mateva L, Njoya O, Al-Busafi SA, Abdelmageed MK, Abdulla M, Adda D, Akin O, Al Baqali A, Al Dweik…
The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm: Volume 4
Chan HLY, Chen CJ, Omede O, Al Qamish J, Al Naamani K, Bane A, Tan SS, Simonova M, Cardenas I, Derbala M, Akin O, Phillips RO, Abdelmageed MK, Abdulla M, Adda D, Al Baqali A,…
Historical epidemiology of hepatitis C virus in select countries-volume 4
Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al…
Estimating HCV disease burden-volume 4 (editorial)
Dore GJ, Hatzakis A, Negro F, Waked I. Estimating HCV disease burden-volume 4 (editorial). J Viral Hepat. 2017 Oct;24 Suppl 2:4-7. doi: 10.1111/jvh.12763. PMID: 29105284. Summary Hepatitis C virus (HCV) is a major global public…
Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey
Örmeci N, Malhan S, Balık İ, Ergör G, Razavi H, Robbins S. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. Hepatol Int. 2017 Nov;11(6):509-516. doi: 10.1007/s12072-017-9820-3. Epub…
Colorado Prevalence and Incidence of Hepatitis C Virus Infection: A Modeling Study
Center for Disease Analysis. Colorado Prevalence and Incidence of Hepatitis C Virus Infection: A Modeling Study. Sept. 2017.
Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study
Gunter J, Callens S, De Wit S, Goffard JC, Moutschen M, Darcis G, Meuris C, van den Bulcke C, Fombellida K, Del Forge M, Razavi H, Wyndham-Thomas C. Prevalence of non-infectious comorbidities in the HIV-positive…
Estimates of the coverage of diagnosis and treatment for HBV and HCV infection, by WHO region and income group, 2015
Center for Disease Analysis. Estimates of the coverage of diagnosis and treatment for HBV and HCV infection, by WHO region and income group, 2015. April 2017. Summary In May 2016, the World Health Assembly endorsed…
A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on a National Strategy for the Elimination of Hepatitis B and C. A National Strategy…
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017 May;2(5):325-336. doi:…
Hepatitis C virus infection
Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017 Mar 2;3:17006. doi: 10.1038/nrdp.2017.6. PMID: 28252637. Summary Hepatitis C virus (HCV) is…
Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System
Buti M, Calleja JL, García-Samaniego J, Serra MÁ, Crespo J, Romero M, Simón MÁ, Turnes J, Blasco AJ, Lázaro P, Robbins S, Razavi H; en representación del Grupo para el Estudio y Modelización Epidemiológica de…
Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment
Hajarizadeh B, Grebely J, McManus H, Estes C, Razavi H, Gray RT, Alavi M, Amin J, McGregor S, Sievert W, Thompson A, Dore GJ. Chronic hepatitis C burden and care cascade in Australia in the…
Hepatitis B and C in the Spotlight: A public health response in the Americas: 2016
Hepatitis B and C in the Spotlight. A public health response in the Americas, 2016. Washington, D.C. : PAHO; 2016.
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16. PMID: 28404132. Summary Collaborators Polaris…
Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia
Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins…
Global genotype distribution of hepatitis C viral infection among people who inject drugs
Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol. 2016 Dec;65(6):1094-1103. doi: 10.1016/j.jhep.2016.07.042. Epub 2016 Aug 9. PMID: 27520879….
Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination
Soipe AI, Razavi H, Razavi-Shearer D, Galárraga O, Taylor LE, Marshall BDL. Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination. Epidemiol Infect. 2016 Dec;144(16):3376-3386. doi: 10.1017/S0950268816001722. Epub 2016 Aug…
Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece
Gountas I, Sypsa V, Papatheodoridis G, Souliotis G, Razavi H, Hatzakis A. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. J Gastroenterol Hepatol….
Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift
Aljumah AA, Abaalkhail F, Al-Ashgar H, Assiri A, Babatin M, Al Faleh F, Alghamdi A, Al-Hakeem R, Hashim A, Alqutub A, Razavi H, Sanai FM, Al-Swat K, Schmelzer J, Altraif I. Epidemiology, disease burden, and…
Urgent action to fight hepatitis C in people who inject drugs in Europe
Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016 Jun 30;1:2. doi: 10.1186/s41124-016-0011-y. PMID: 30288305; PMCID: PMC5918492. Summary Hepatitis C virus…
Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden
Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat…
Hepatitis C virus infection in Argentina: Burden of chronic disease
Ridruejo E, Bessone F, Daruich JR, Estes C, Gadano AC, Razavi H, Villamil FG, Silva MO. Hepatitis C virus infection in Argentina: Burden of chronic disease. World J Hepatol. 2016 May 28;8(15):649-58. doi: 10.4254/wjh.v8.i15.649. PMID:…
Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium
Matheï C, Bourgeois S, Blach S, Brixko C, Mulkay JP, Razavi H, Robaeys G. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastroenterol Belg. 2016 Apr-Jun;79(2):227-32. PMID: 27382943….
Achieving WHO recommendations for Hepatitis C Virus Elimination in Belgium
Bourgeois S, Blach S, Blach C, Laleman W, Matheï C, Mulkay JP, Ravazi H, Robaeys G, Stärkel P, Van Damme P, Van Vlierberghe H, Vandijck D, Vandijck C. Achieving WHO recommendations for Hepatitis C Virus…
Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis
Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis….
Strategies to manage hepatitis C virus infection disease burden – volume 3
Alfaleh FZ, Nugrahini N, Matičič M, Tolmane I, Alzaabi M, Hajarizadeh B, Valantinas J, Kim DY, Hunyady B, Abaalkhail F, Abbas Z, Abdou A, Abourached A, Al Braiki F, Al Hosani F, Al Jaberi K,…
The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm – volume 3
Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, Salupere R, Assiri AM, Goldis A, Abaalkhail F, Abbas Z, Abdou A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry…
Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3
Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, Gheorghe L, El Hassan ES, Abaalkhail F, Abbas Z, Abdou A, Abourached A, Al Braiki F, Al Hosani F, Al Jaberi K, Al…
Estimating HCV disease burden – volume 3 (editorial)
Aghemo A, Dore GJ, Hatzakis A, Wedemeyer H, Razavi H. Estimating HCV disease burden – volume 3 (editorial). J Viral Hepat. 2015 Dec;22 Suppl 4:1-3. doi: 10.1111/jvh.12473. PMID: 26513444. Countries: Estonia, Hungary, Iceland, Indonesia, Iran,…
Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland
Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Müllhaupt B, Razavi H, Semela D. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Med Wkly. 2015 Dec 4;145:w14221….
The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms
Willemse SB, Razavi-Shearer D, Zuure FR, Veldhuijzen IK, Croes EA, van der Meer AJ, van Santen DK, de Vree JM, de Knegt RJ, Zaaijer HL, Reesink HW, Prins M, Razavi H. The estimated future disease…
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, Brauer M, Burnett R, Casey D, Coates MM, Cohen A, Delwiche K, Estep K, Frostad JJ, Astha KC, Kyu HH,…
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition
GBD 2013 DALYs and HALE Collaborators, Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd-Allah F, Abera SF, Aboyans V, Abraham JP, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NM, Achoki T, Ackerman IN, Ademi Z,…
Interferon-based hepatitis C antiviral treatment outcomes may be predicted by alanine aminotransferase levels
Kelly E, Blach S, Razavi H, Cooper C. Interferon-based hepatitis C antiviral treatment outcomes may be predicted by alanine aminotransferase levels. Can J Gastroenterol Hepatol. 2015 Nov-Dec;29(8):407-8. doi: 10.1155/2015/897035. Epub 2015 Aug 24. PMID: 26301333;…
Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies
Estes C, Abdel-Kareem M, Abdel-Razek W, Abdel-Sameea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment…
Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland
Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS One. 2015 Jun 24;10(6):e0125214. doi: 10.1371/journal.pone.0125214….
The Disease Burden of Hepatitis C in Belgium: An update of a realistic disease control strategy
Stärkel P, Vandijck D, Laleman W, Van Damme P, Moreno C, Blach S, Razavi H, Van Vlierberghe H. The Disease Burden of Hepatitis C in Belgium : An update of a realistic disease control strategy. Acta…
Disease burden of chronic hepatitis C in Brazil
Ferreira PR, Brandão-Mello CE, Estes C, Gonçales Júnior FL, Coelho HS, Razavi H, Cheinquer H, Wolff FH, Ferraz ML, Pessoa MG, Mendes-Correa MC. Disease burden of chronic hepatitis C in Brazil. Braz J Infect Dis….
HCV-infected patients need access now to new direct-acting antiviral agents to avert liver- related deaths
Sievert W, Razavi H, Thompson A, Zekry A, Dore GJ, Roberts SK. HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths. Med J Aust. 2015 May 18;202(9):479. doi: 10.5694/mja15.00165. PMID:…
Forecasting the disease burden of chronic hepatitis C virus in Poland
Flisiak R, Halota W, Tomasiewicz K, Kostrzewska K, Razavi HA, Gower EE. Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur J Gastroenterol Hepatol. 2015 Jan;27(1):70-6. doi: 10.1097/MEG.0000000000000237. PMID: 25426979. Summary Background…
Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2
Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, Shestakova I, Nymadawa P, Blach S, Acharya S, Anand AC, Andersson MI, Arendt V, Arkkila P, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin…
The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm – volume 2
Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina…
Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2
Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin…
Estimates on HCV disease burden worldwide – filling the gaps
Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide – filling the gaps. J Viral Hepat. 2015 Jan;22 Suppl 1:1-5. doi: 10.1111/jvh.12371. PMID: 25560838. Summary Hepatitis C is caused by infection with…
Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand
Gane E, Stedman C, Brunton C, Radke S, Henderson C, Estes C, Razavi H. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand. N Z Med J. 2014 Dec 19;127(1407):61-74….
The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies
Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015 Feb;50(2):233-44….
Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end‐stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue
Razavi H, Bruggmann P, Wedemeyer H, Dore G. Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not…
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality
Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol. 2014…
Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia
Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J…
Global epidemiology and genotype distribution of the hepatitis C virus infection
Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014 Nov;61(1 Suppl):S45-57. doi: 10.1016/j.jhep.2014.07.027. Epub 2014 Jul 30. PMID: 25086286. Summary…
Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, Dansereau EA, Graetz N, Barber RM, Brown JC, Wang H, Duber HC, Naghavi M, Dicker D, Dandona L, Salomon JA, Heuton KR, Foreman…
Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy
Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxì A. Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res. 2014 Jun 19;6:303-10….
The current and future disease burden of chronic hepatitis C virus infection in Egypt
Waked I, Doss W, El-Sayed MH, Estes C, Razavi H, Shiha G, Yosry A, Esmat G. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol. 2014 Jun;15(2):45-52….
Current and future health and economic impact of hepatitis C in Belgium
Vandijck D, Moreno C, Stärkel P, Van Damme P, Van Vlierberghe H, Hindman SJ, Razavi H, Laleman W. Current and future health and economic impact of hepatitis C in Belgium. Acta Gastroenterol Belg. 2014 Jun;77(2):285-90….
The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy
Stärkel P, Vandijck D, Laleman W, Van Damme P, Moreno C, Hindman S, Razavi H, Van Vlierberghe H. The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy. Acta Gastroenterol…
Hepatitis C epidemiology in Belgium
Van Damme P, Laleman W, Stärkel P, Van Vlierberghe H, Vandijck D, Hindman SJ, Razavi H, Moreno C. Hepatitis C epidemiology in Belgium. Acta Gastroenterol Belg. 2014 Jun;77(2):277-9. PMID: 25090833. Summary Background The burden of…
Innovative strategies for hepatitis C in Belgium integrating treatment efficacy, public disease burden, and healthcare costs
Vandijck D, Stärkel P. Innovative strategies for hepatitis C in Belgium integrating treatment efficacy, public disease burden, and healthcare costs. Acta Gastroenterol Belg. 2014 Jun;77(2):274-6. PMID: 25090832. Countries: Belgium
Burden of disease and cost of chronic hepatitis C infection in Canada
Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, Ramji A, Estes C, Razavi H, Sherman M. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol…
Strategies to manage hepatitis C virus (HCV) disease burden
Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello…
The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm
Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ,…
Historical epidemiology of hepatitis C virus (HCV) in selected countries
Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F,…
Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward)
Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat. 2014 May;21 Suppl 1:1-4. doi: 10.1111/jvh.12253. PMID:…
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New…
Hepatitis C medicines and diagnostics in the context of HIV/HCV co-infection: A scoping report
Deelder W, Eustance J, Pingali P et al. Hepatitis C medicines and diagnostics in the context of HIV/HCV co-infection: A scoping report. UNITAID; 2013 Oct 1.
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors
Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, Dellavalle R, Danaei G, Ezzati M, Fahimi A, Flaxman D, Foreman, Gabriel S, Gakidou E, Kassebaum N, Khatibzadeh S, Lim S, Lipshultz SE,…
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013 Jun;57(6):2164-70. doi: 10.1002/hep.26218. Epub 2013 May…
HCV infection prevalence in a population recruited at health centers in Jordan
Hamoudi W, Ali SA, Abdallat M, Estes CR, Razavi HA. HCV infection prevalence in a population recruited at health centers in Jordan. J Epidemiol Glob Health. 2013 Jun;3(2):67-71. doi: 10.1016/j.jegh.2013.02.003. Epub 2013 Mar 19. PMID:…
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson…
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell…
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson…
Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas
El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ. 2012;15(5):887-96. doi: 10.3111/13696998.2012.681332. Epub 2012 May 24. PMID: 22458755. Summary Background…
Economic burden of hepatitis C-associated diseases in the United States
El Khoury AC, Klimack WK, Wallace C, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012 Mar;19(3):153-60. doi: 10.1111/j.1365-2893.2011.01563.x. Epub 2011 Dec 18. PMID: 22329369. Summary There are…
Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data
Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, Zeuzem S, Negro F. Applying a system approach to forecast the total hepatitis C virus-infected…
The global health burden of hepatitis C virus infection
Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int. 2011 Jul;31 Suppl 2:1-3. doi: 10.1111/j.1478-3231.2011.02537.x. PMID: 21651699. Countries: Brazil, Argentina, Puerto Rico, Mexico, United States, Canada, United Kingdom, Germany,…
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G,…
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara…
Trends and projections of hepatitis C virus epidemiology in Latin America
Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, Quiroz JF, Rodriguez-Perez F, Rosado B, Wallace C, Negro F, Silva M. Trends and projections of hepatitis C virus epidemiology in…